Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2005

01-09-2005 | Article

A 100-kDa urinary protein is associated with insulin resistance in offspring of type 2 diabetic patients

Authors: A. Pätäri, P. Karhapää, H. Taipale, U. Salmenniemi, E. Ruotsalainen, P. Vanninen, H. Holthöfer, M. Laakso

Published in: Diabetologia | Issue 9/2005

Login to get access

Abstract

Aims/hypothesis

One-third of normoalbuminuric type 1 diabetic patients show immunoreactive nephrin in urine. Offspring of type 2 diabetic patients are insulin-resistant and susceptible to the development of diabetes. We investigated whether the offspring of type 2 diabetic patients show nephrin in urine and whether possible nephrinuria is associated with insulin resistance.

Methods

Urinary proteins from timed overnight urine collections from 128 offspring of type 2 diabetic patients and 9 control subjects were analysed by western blotting using an antibody against nephrin. Glucose metabolism was assessed by OGTT and IVGTT and the euglycaemic–hyperinsulinaemic clamp technique.

Results

Of the offspring, 12.5% were strongly and 14.1% weakly positive for a 100-kDa urinary protein. All controls were negative. During the first 10 min of an IVGTT, the offspring strongly positive for the urinary protein had a higher insulin response than the offspring without the protein (3,700 vs 2,306 pmol l−1min−1, p=0.007). Insulin sensitivity (the rate of whole-body glucose uptake divided by the steady-state insulin level×100) was lower among the offspring strongly positive for the urinary protein than among the offspring negative for the protein (11.3 vs 15.8 μmol kg−1min−1pmol−1l−1, p=0.008).

Conclusions/interpretation

A 100-kDa urinary protein detectable with a nephrin antibody is associated with insulin resistance in offspring of type 2 diabetic patients.
Literature
1.
DeFronzo RA (1988) Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667–687PubMed
2.
Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 15:815–819PubMed
3.
Uusitupa M, Siitonen O, Penttila I, Aro A, Pyorala K (1987) Proteinuria in newly diagnosed type II diabetic patients. Diabetes Care 10:191–194PubMed
4.
Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P (2000) Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 26:8–14PubMed
5.
Fioretto P, Mauer M, Brocco E et al (1996) Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39:1569–1576PubMed
6.
Groop L, Ekstrand A, Forsblom C et al (1993) Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36:642–647PubMed
7.
Forsblom CM, Eriksson JG, Ekstrand AV, Teppo AM, Taskinen MR, Groop LC (1995) Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia 38:363–369PubMed
8.
Rodewald R, Karnovsky MJ (1974) Porous substructure of the glomerular slit diaphragm in the rat and mouse. J Cell Biol 60:423–433PubMed
9.
Holzman LB, St John PL, Kovari IA, Verma R, Holthofer H, Abrahamson DR (1999) Nephrin localizes to the slit pore of the glomerular epithelial cell. Kidney Int 56:1481–1491PubMed
10.
Kestila M, Lenkkeri U, Mannikko M et al (1998) Positionally cloned gene for a novel glomerular protein–nephrin is mutated in congenital nephrotic syndrome. Mol Cell 1:575–582PubMed
11.
Palmen T, Ahola H, Palgi J et al (2001) Nephrin is expressed in the pancreatic beta cells. Diabetologia 44:1274–1280PubMed
12.
Aaltonen P, Luimula P, Astrom E et al (2001) Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 81:1185–1190PubMed
13.
Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z (2001) Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44:874–877PubMed
14.
Langham RG, Kelly DJ, Cox AJ, Gow RM, Holthofer H, Gilbert RE (2004) Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrol Dial Transplant 19:262–263PubMed
15.
Koop K, Eikmans M, Baelde HJ et al (2003) Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 14:2063–2071PubMed
16.
Pätäri A, Forsblom C, Havana M et al (2003) Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 52:2969–2974PubMed
17.
Nakamura T, Ushiyama C, Suzuki S et al (2000) Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15:1379–1383PubMed
18.
Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P (2003) Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 52:1031–1035PubMed
19.
Metcalf PA, Baker JR, Scragg RK, Dryson E, Scott AJ, Wild CJ (1993) Microalbuminuria in a middle-aged workforce. Effect of hyperglycemia and ethnicity. Diabetes Care 16:1485–1493PubMed
20.
Haffner SM, Stern MP, Gruber MK, Hazuda HP, Mitchell BD, Patterson JK (1990) Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 10:727–731PubMed
21.
Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M (1998) Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. J Clin Invest 101:86–96PubMed
22.
Holthofer H, Ahola H, Solin ML et al (1999) Nephrin localizes at the podocyte filtration slit area and is characteristically spliced in the human kidney. Am J Pathol 155:1681–1687PubMed
23.
Gagliardini E, Benigni A, Tomasoni S, Abbate M, Kalluri R, Remuzzi G (2003) Targeted downregulation of extracellular nephrin in human IgA nephropathy. Am J Nephrol 23:277–286PubMed
24.
Topham PS, Kawachi H, Haydar SA et al (1999) Nephritogenic mAb 5-1-6 is directed at the extracellular domain of nephrin. J Clin Invest 104:1559–1566PubMed
25.
Kelly DJ, Aaltonen P, Cox AJ et al (2002) Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 17:1327–1332PubMed
26.
Langham RG, Kelly DJ, Cox AJ et al (2002) Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45:1572–1576PubMed
27.
Doublier S, Salvidio G, Lupia E et al (2003) Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52:1023–1030PubMed
28.
Furuhashi M, Ura N, Higashiura K et al (2003) Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76–81PubMed
29.
Hansson L, Lindholm LH, Niskanen L et al (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet 353:611–616PubMed
30.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342:145–153PubMed
31.
Lindholm LH, Ibsen H, Borch-Johnsen K et al (2002) Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in Hypertension Study. J Hypertens 20:1879–1886PubMed
32.
Julius S, Kjeldsen SE, Weber M et al (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031PubMed
33.
Nosadini R, Cipollina MR, Solini A et al (1992) Close relationship between microalbuminuria and insulin resistance in essential hypertension and non-insulin dependent diabetes mellitus. J Am Soc Nephrol 3:S56–S63PubMed
34.
Niskanen L, Laakso M (1993) Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus. Metab Clin Exp 42:1541–1545PubMed
35.
Toft I, Bonaa KH, Eikrem J, Bendiksen AL, Iversen H, Jenssen T (2002) Microalbuminuria in hypertension is not a determinant of insulin resistance. Kidney Int 61:1445–1452PubMed
36.
Halimi JM, Forhan A, Balkau B et al (2001) Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk 8:139–146PubMed
37.
Pagtalunan ME, Miller PL, Jumping-Eagle S et al (1997) Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342–348PubMed
38.
Christensen EI, Nielsen S (1991) Structural and functional features of protein handling in the kidney proximal tubule. Semin Nephrol 11:414–439PubMed
Metadata
Title
A 100-kDa urinary protein is associated with insulin resistance in offspring of type 2 diabetic patients
Authors
A. Pätäri
P. Karhapää
H. Taipale
U. Salmenniemi
E. Ruotsalainen
P. Vanninen
H. Holthöfer
M. Laakso
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1853-9

Other articles of this Issue 9/2005

Diabetologia 9/2005 Go to the issue

Article

Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes

Article

A novel complex of arginine–silicate improves micro- and macrovascular function and inhibits glomerular sclerosis in insulin-resistant JCR:LA-cp rats

Article

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

Article

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig

Review

The metabolic syndrome: time for a critical appraisal

Short Communication

Increased expression of inflammation-related genes in cultured preadipocytes/stromal vascular cells from obese compared with non-obese Pima Indians
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits